Dietary Docosahexaenoic Acid Levels Research Articles

Growth performance and gene expression in gilthead sea bream (Sparus aurata) fed microdiets with high docosahexaenoic acid and antioxidant levels

This study aimed to determine the effects of increasing docosahexaenoic acid (DHA) levels in Sparus aurata diets supplemented with antioxidants vitamins (vitamins C and E). Six isoproteic and isolipidic formulated diets, which varied in the DHA content (38–78 g kg−1 TFA), were fed to 19 dph S. aurata larvae. No significant differences were found in survival rates or growth, which indicates that all the diets covered the minimum essential fatty acid requirements of this species. Stress resistance was not negatively affected by dietary DHA contents. In agreement, two biomarkers of the oxidative stress of the fish and the gene expression of superoxide dismutase and glutathione peroxidase were not affected by the elevation of dietary DHA, denoting that fish were sufficiently protected from oxidative damage even at high dietary DHA contents. The elevation of dietary DHA did affect neither the occurrence of skeletal malformations nor the expression of osteological markers such as run-related transcription factor 2 or alkaline phosphatase. The results of this study have confirmed that increase of the dietary DHA levels in gilthead sea bream diets does not negatively affect larval performance if the larvae are protected from peroxidation risks. Despite not being harmful, increase of DHA over the recommended requirements does not have any significant improvement in larval performance.

Influence of hormonal induction and broodstock feeding on longfin yellowtailSeriola rivolianamaturation, spawning quality and egg biochemical composition

To optimize broodstock management for Seriola rivoliana, a survey over 5 years was performed to evaluate the effects of successive hormonal inductions with GnRHa or dietary regime on spawning quality. Running males and females with an oocyte diameter > 500 μm were injected with GnRHa. The spawning quality was compared among consecutive years and different moments along the spawning season. Besides, three different feeding regimes were tested. Spawning quality parameters were not significantly affected by time along the spawning season, whereas they were clearly influenced by diet. Particularly, broodfish fed the mackerel regime (M) showed a significantly higher number of eggs than other treatments. Besides, dietary protein content significantly improved broodstock fecundity of S. rivoliana. Moreover, hatching rates were also higher in broodfish fed mackerel and the dietary docosahexaenoic acid (DHA) levels significantly increased this parameter. Despite polar lipids were not significantly affected, neutral lipids fatty acid composition of S. rivoliana eggs showed higher 18:2n-6 in eggs, whereas ARA content was not affected. The results of this study denoted the high fecundity and good spawning quality of S. rivoliana broodfish and suggested the importance of high protein, energy and DHA levels in broodstock diets.

Growth and Fatty Acid Composition of Juvenile Olive Flounder Paralichthys olivaceus Fed Diets Containing Different Levels and Ratios of Eicosapentaenoic Acid and Docosahexaenoic Acid

This study was carried out to investigate the influences of dietary levels, ratios and sources of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the growth and fatty acid compositions of juvenile olive flounder Paralichthys olivaceus. Sixteen diets containing five levels of EPA (0.5%, 1.0%, 1.5%, 2.0%, and 4.0%), five levels of DHA (0.5%, 1.0%, 1.5%, 2.0% and 4.0%), three ratios of EPA/DHA (75/25, 50/50 and 25/75), two levels of squid liver oil (5% and 10%) and a control diet containing 5% soybean oil were hand-fed to triplicate groups of fish (average weight, 9.7 ± 0.3 g) for 8 weeks. Survival, specific growth rate, feed efficiency and protein efficiency ratio of fish were not affected by dietary EPA and DHA levels or ratios. Also, the dietary treatment had no significant effect on the lipid and protein contents of muscle and whole body of fish. A corresponding increase in the EPA and DHA contents of fish occurred with increasing EPA and DHA levels in their diets. Our results suggest that juvenile olive flounder require a dietary EPA level of approximately 0.32% in the presence of 0.74% DHA for sui table survival and growth, and that EPA and DHA levels in fish muscle can increase to as much as 32% and 53%, respectively, of the total fatty acid content.

Fish in the diet: A review

Fish in the diet: A review

Randomized Controlled Trial of Docosahexaenoic Acid Supplementation in Midwestern U.S. Human Milk Donors

Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid important for neonatal neurodevelopment and immune homeostasis. Preterm infants fed donor milk from a Midwestern source receive only 20% of the intrauterine accretion of DHA. We tested the hypothesis that DHA supplementation of donor mothers would provide preterm infants with DHA intake equivalent to fetal accretion. After Institutional Review Board approval and informed consent, human milk donors to the Mother's Milk Bank of Ohio were randomized to receive 1 g of DHA (Martek(®) [now DSM Nutritional Lipids, Columbia, MD]) or placebo soy oil. Dietary intake data were collected and analyzed by a registered dietitian. Fatty acids were measured by gas chromatography/flame ionization detection. Statistical analysis used linear mixed models. Twenty-one mothers were randomly assigned to either the DHA group (n=10) or the placebo group (n=11). Donor age was a median of 31 years in both groups with a mean lactational stage of 19 weeks. Dietary intake of DHA at baseline in both groups was a median of 23 mg/day (range, 0-194 mg), significantly (p<0.0001) less than the minimum recommended intake of 200 mg/day. The DHA content of milk increased in the DHA-supplemented group (p<0.05). The women enrolled in this study had low dietary DHA intake. Supplementation with preformed DHA at 1 g/day resulted in increased DHA concentrations in the donor milk with no adverse outcomes. Infants fed donor milk from supplemented women receive dietary DHA levels that closely mimic normal intrauterine accretion during the third trimester.

Omega-3 Fatty Acid Deficiency during Brain Maturation Reduces Neuronal and Behavioral Plasticity in Adulthood

Omega-3-fatty acid DHA is a structural component of brain plasma membranes, thereby crucial for neuronal signaling; however, the brain is inefficient at synthesizing DHA. We have asked how levels of dietary n-3 fatty acids during brain growth would affect brain function and plasticity during adult life. Pregnant rats and their male offspring were fed an n-3 adequate diet or n-3 deficient diets for 15 weeks. Results showed that the n-3 deficiency increased parameters of anxiety-like behavior using open field and elevated plus maze tests in the male offspring. Behavioral changes were accompanied by a level reduction in the anxiolytic-related neuropeptide Y-1 receptor, and an increase in the anxiogenic-related glucocorticoid receptor in the cognitive related frontal cortex, hypothalamus and hippocampus. The n-3 deficiency reduced brain levels of docosahexaenoic acid (DHA) and increased the ratio n-6/n-3 assessed by gas chromatography. The n-3 deficiency reduced the levels of BDNF and signaling through the BDNF receptor TrkB, in proportion to brain DHA levels, and reduced the activation of the BDNF-related signaling molecule CREB in selected brain regions. The n-3 deficiency also disrupted the insulin signaling pathways as evidenced by changes in insulin receptor (IR) and insulin receptor substrate (IRS). DHA deficiency during brain maturation reduces plasticity and compromises brain function in adulthood. Adequate levels of dietary DHA seem crucial for building long-term neuronal resilience for optimal brain performance and aiding in the battle against neurological disorders.

α‐Synuclein Neuropathology is Controlled by Nuclear Hormone Receptors and Enhanced by Docosahexaenoic Acid in A Mouse Model for Parkinson's Disease

α-Synuclein (α-Syn) is a neuronal protein that accumulates progressively in Parkinson's disease (PD) and related synucleinopathies. Attempting to identify cellular factors that affect α-Syn neuropathology, we previously reported that polyunsaturated fatty acids (PUFAs) promote α-Syn oligomerization and aggregation in cultured cells. We now report that docosahexaenoic acid (DHA), a 22:6 PUFA, affects α-Syn oligomerization by activating retinoic X receptor (RXR) and peroxisome proliferator-activated receptor γ2 (PPARγ2). In addition, we show that dietary changes in brain DHA levels affect α-Syn cytopathology in mice transgenic for the PD-causing A53T mutation in human α-Syn. A diet enriched in DHA, an activating ligand of RXR, increased the accumulation of soluble and insoluble neuronal α-Syn, neuritic injury and astrocytosis. Conversely, abnormal accumulations of α-Syn and its deleterious effects were significantly attenuated by low dietary DHA levels. Our results suggest a role for activated RXR/PPARγ 2, obtained by elevated brain PUFA levels, in α-Syn neuropathology.

The role of n-3 dietary polyunsaturated fatty acids in brain function and ameliorating Alzheimer's disease: Opportunities for biotechnology in the development of nutraceuticals

Prospective epidemiological surveys and numerous animal studies have shown an important role for dietary docosahexaenoic acid (DHA) in healthy brain function and reducing the risk of dementia. The evidence for this is summarised and some further experiments of our own are described. For the experimentation we have used the Tg2576 mouse, which is a well known model of amyloid pathology and cognitive impairment as seen in Alzheimer's disease. We found that, while brain levels of DHA showed a positive correlation with behaviour and a negative correlation with insoluble β-amyloid (1-40), the general benefits of DHA-enriched diets were not as great as have sometimes been reported in the literature. This may be due to either the age of the animals we tested and/or the fact that we examined the effects of DHA supplementation against a normal healthy control diet condition, unlike previous studies, in order to mimic dietary supplement use in the human population. In addition, we point to some ways in which biotechnology could be used to supplement the world's supply of omega-3 PUFAs (especially DHA) since there is an increasing shortage of such compounds for dietary consumption.

Cognitive function in 18-month-old term infants of the DIAMOND study: A randomized, controlled clinical trial with multiple dietary levels of docosahexaenoic acid

Background Studies investigating cognitive outcomes following docosahexaenoic acid (DHA) supplementation of infant formula yield conflicting results, perhaps due to inadequate dietary concentrations. Aim To determine the optimal DHA concentration in term formula to support cognitive maturation. Design This was a double-masked, randomized, controlled, prospective trial. A total of 181 infants were enrolled at 1–9 days of age and assigned randomly to receive one of four term infant formulas with one of four levels of docosahexaenoic acid: Control (0% DHA), 0.32% DHA, 0.64% DHA, or 0.96% DHA. All DHA-supplemented formulas contained 0.64% arachidonic acid (ARA). Infants were fed the assigned formulas until 12 months of age. One hundred forty-one children completed the 12-month feeding trial and were eligible for this study. Cognitive function was assessed in 131 children at 18 months of age using the Bayley Scales of Infant Development II (BSID II). Results There were no diet group differences on the Mental Development Index (MDI), the Psychomotor Development Index (PDI), or the Behavior Rating Scale (BRS) of the BSID II. However, when the scores of children who received any of the three DHA-supplemented formulas were combined and compared to control children, a significant difference emerged: the MDI scores of DHA-supplemented children were higher (104.1 v. 98.4; p = 0.02). Conclusions These results suggest that dietary supplementation of DHA during the first year of life leads to enhanced cognitive development at 18 months of age. DHA concentration of 0.32% is adequate to improve cognitive function; higher concentrations did not confer additional benefit.

Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial

Objective: Best disease is a slowly progressive macular dystrophy that typically has an onset in early childhood. Multiple lines of evidence suggest that dietary docosahexaenoic acid (DHA) protects against the development of macular degeneration. Our trial tested the effect of an oral supplement of DHA on visual function in patients with Best disease. Design: Double-masked, randomized, placebo-controlled, crossover clinical trial. Participants: Eight patients with Best disease. Methods: Patients were given either an oral supplement of DHA (20 mg/kg daily) or placebo. Primary outcome measures were the multifocal electroretinogram (mfERG) and electro-oculogram (EOG). Plasma DHA was tracked along with visual acuity (Early Treatment Diabetic Retinopathy Study chart), VF-14 scores, and Humphrey visual fields. Results: All 8 patients had increased plasma DHA levels (2–3 fold) during periods of DHA supplementation compared with periods without supplementation. Differences in visual acuity, VF-14 scores, and EOG Arden ratios during periods with and without DHA supplementation were all statistically insignificant. A positive correlation was found between the plasma concentration of DHA and mfERG amplitudes, but amplitude changes during the treatment periods were not significant. A carryover effect of DHA supplementation was a confounding error. Conclusions: Our pilot trial of DHA supplementation in 8 patients with Best disease did not demonstrate an improvement in macular function. An expanded trial would be needed to examine the full effects of DHA supplementation on visual function in Best disease.

Effects of dietary docosahexaenoic acid (22:6n-3) and arachidonic acid (20:4n-6) on the growth, survival, stress resistance and fatty acid composition in black sea bass Centropristis striata (Linnaeus 1758) larvae

The objectives of this study were to determine the effects of the dietary docosahexaenoic acid (DHA) to arachidonic acid (ARA) ratio on the survival, growth, hypersaline stress resistance and tissue composition of black sea bass larvae raised from first feeding to metamorphic stages. Larvae were fed enriched rotifers Brachionus rotundiformis and Artemia nauplii containing two levels of DHA (0% and 10% total fatty acids=TFA) in conjunction with three levels of ARA (0%, 3% and 6% TFA). On d24ph, larvae fed the 10:6 (DHA:ARA) treatment showed significantly (P<0.05) higher survival (62.3%) than larvae fed 0:0 (DHA:ARA) (27.4%). Notochord length and dry weight were also significantly (P<0.05) greater in the 10:6 (DHA:ARA) treatment (8.65 mm, 2.14 mg) than in the 0:0 (DHA:ARA) (7.7 mm, 1.65 mg) treatment. During hypersaline (65 g L−1) challenge, no significant differences (P>0.05) were observed in the median survival time (ST50) between larvae fed 10% DHA (ST50=25.6 min) and larvae fed 0% DHA (ST50=18.2 min). The results suggested that black sea bass larvae fed prey containing 10% DHA with increasing ARA within the range of 0–6% showed improved growth and survival from first feeding through metamorphic stages.

The effect of dietary docosahexaenoic acid (DHA) on growth, survival and pigmentation of California halibut Paralichthys californicus larvae (Ayres, 1810)

The California halibut (Paralichthys californicus) is a good candidate for aquaculture due to its good growth, survival and high commercial value. Several farms in the Western coast of North America are currently evaluating the potential of this species under commercial conditions. However, one of the main problems in the production of juveniles for commercial purposes is the high percentage of malpigmented fish obtained after metamorphosis (up to 80%). This problem seems to be related, among other things, to nutritional deficiencies during the larval period, in particular to the quantities and proportions of highly unsaturated fatty acids (HUFAs) in the diet. As a first approach to reduce malpigmentation, improve growth and determine the requirement for DHA in California halibut late larvae, we evaluated the effect of four levels of dietary DHA (0, 1, 2, and 4% of total fatty acids in the diet) on growth, survival, weaning success and pigmentation. DHA was administered to the larvae through enriched Artemia metanauplii. Larvae standard length and wet weight were taken during the initial stage of Artemia metanauplii supplementation (18 days post hatch, dph); at the beginning of the weaning period (50 dph); and at the end of the experiment (75 dph). We quantified the amounts of total fatty acids in 18 and 50 dph larvae. No significant differences on growth, survival and pigmentation as a result of increasing dietary DHA levels were found in 50 dph recently settled juveniles. However, larvae fed the highest DHA level resulted in the highest growth and survival at the end of the experiment (75 dph). Additionally, highest weaning success was achieved with this treatment. Significantly higher numbers of normally pigmented fish (ca., 33%) were obtained with the highest DHA level at 75 dph compared to the low DHA levels (0 and 5%). However, since this treatment resulted in the highest survival, part of the population had abnormal pigmentation (ca., 30% of the population). Based on a second order polynomial regression, the recommended DHA level in the diet for pre-metamorphic larvae to attain adequate growth and survival as estimated here for recently settled California halibut at 50 dph was 1.21% DHA of total fatty acids (TFA). However, for post-metamorphosis fish (75 dph) highest pigmentation rates, growth and survival are obtained with 2.40% DHA of TFA in the diet during the Artemia feeding period.

Toward optimizing vision and cognition in term infants by dietary docosahexaenoic and arachidonic acid supplementation: A review of randomized controlled trials

The question of whether a dietary supply of docosahexaenoic acid (DHA) and arachidonic acid (ARA) imparts advantages to visual or cognitive development in term infants has been debated for many years. DHA and ARA are present in human milk, and nursing infants consume these fatty acids needed for rapid synthesis of cell membranes, particularly neural cells. The reported mean DHA and ARA levels of human milk worldwide are 0.32% and 0.47% of total fatty acids, respectively. Prior to 2002 in the US, formula-fed infants did not receive these fatty acids and relied solely on endogenous conversion of the dietary essential omega-3 (n-3) and omega-6 (n-6) fatty acids, α-linolenic and linoleic acids, to DHA and ARA, respectively. Formula-fed infants were found to have significantly less accretion of DHA in brain cortex after death than breastfed infants. Numerous studies have found positive correlations between blood DHA levels and improvements in cognitive or visual function outcomes of breastfed and formula-fed infants. Results of randomized controlled clinical trials of term formula-fed infants evaluating functional benefits of dietary DHA and ARA have been mixed, likely due to study design heterogeneity. A comparison of visual and cognitive outcomes in these trials suggests that dietary DHA level is particularly relevant. Trials with formulas providing close to the worldwide human milk mean of 0.32% DHA were more likely to yield functional benefits attributable to DHA. We agree with several expert groups in recommending that infants receive at least 0.3% DHA, with at least 0.3% ARA, in infant feedings; in addition, some clinical evidence suggests that an ARA:DHA ratio greater than 1:1 is associated with improved cognitive outcomes.

Influence of maternal immune activation in embryonic stage on hippocampal function in juvenile stage

The prevalence of autism spectrum disorders over the last several decades has risen at an alarming rate. Factors such as broadened clinical definitions and increased parental age only partially account for this precipitous increase, suggesting that recent changes in environmental factors may also be responsible. One such factor could be the dramatic decrease in consumption of anti-inflammatory dietary omega-3 (n-3) polyunsaturated fatty acids (PUFAs) relative to the amount of pro-inflammatory omega-6 (n-6) PUFAs and saturated fats in the Western diet. Docosahexaenoic acid (DHA) is the principle n-3 PUFA found in neural tissue and is important for optimal brain development, especially during late gestation when DHA rapidly and preferentially accumulates in the brain. In this study, we tested whether supplementation of a low n-3 PUFA diet with DHA throughout development could improve measures related to autism in a mouse model of maternal immune activation. We found that dietary DHA protected offspring from the deleterious effects of gestational exposure to the viral mimetic polyriboinosinic–polyribocytidilic acid on behavioral measures of autism and subsequent adulthood immune system reactivity. These data suggest that elevated dietary levels of DHA, especially during pregnancy and nursing, may help protect normal neurodevelopment from the potentially adverse consequences of environmental insults like maternal infection.

The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition

Numerous studies on perinatal long-chain polyunsaturated fatty acid nutrition have clarified the influence of dietary docosahexaenoic acid (DHA) and arachidonic acid (ARA) on central nervous system PUFA concentrations. In humans, omnivorous primates, and piglets, DHA and ARA plasma and red blood cells concentrations rise with dietary preformed DHA and ARA. Brain and retina DHA are responsive to diet while ARA is not. DHA is at highest concentration in cells and tissues associated with high energy consumption, consistent with high DHA levels in mitochondria and synaptosomes. DHA is a substrate for docosanoids, signaling compounds of intense current interest. The high concentration in tissues with high rates of oxidative metabolism may be explained by a critical role related to oxidative metabolism.

Plasma and brain endocannabinoid level correlation studies after increasing DHA dietary intake

We utilized a mouse model to demonstrate the correlation between plasma and brain levels of endocannabinoids following an increase in dietary docosahexaenoic acid (DHA). Two groups of 10 mice received either normal lab chow or chow formulated with low eicosapentaenoic acid (EPA)/high DHA fish oil. Mice were sacrificed by decapitation followed by plasma and brain collection for analysis by LC-MS. Mice on the DHA food ate 4.79 ± 0.22 g of food per day, correlating to an average daily intake of 53.64 mg DHA. Most of the measured fatty acid levels remained constant after two weeks on the DHA food compared to control food; however, DHA, EPA and their derivatives did change. While DHA and DHEA levels increased in plasma, they did not in brain. When comparing DHEA levels with respect to anandamide (AEA), there is an increase in both brain and plasma; comparing 2-DHG to 2-arachidonoylglycerol (2-AG) only shows an increase in plasma. Although the EPA content in the DHA food was only 0.17%, resulting in 8.04 mg/day dietary intake, the levels of both EPA and 2-EPG in brain and plasma increased. Conclusion: An increase in dietary fatty acid results in an increase in plasma fatty acid and the respective ethanolamide. This data supports the idea that increase in dietary DHA can affect ethanolamide and glycerol synthesis in favor of the docosahexaenoic derivatives over the arachidonoyl derivatives.

Docosahexaenoic acid-enriched egg consumption induces accretion of arachidonic acid in erythrocytes of elderly patients.

Many studies in humans volunteers have shown that dietary docosahexaenoic acid (DHA) supplied as triacylglycerol can increase DHA levels in blood lipids but often strongly decreases those of arachidonic acid (AA). The aim of the present study was to determine the effect of dietary supplementation with egg-yolk powder enriched in DHA, corresponding to the French recommended dietary allowance for DHA, on the blood lipid status of an elderly population. Institutionalised elderly individuals aged between 63 and 93 years consumed an egg product enriched in DHA (150 mg/d) once daily for 9 months. Plasma lipids and the fatty acid composition of erythrocyte membranes were determined every 3 months. The supplementation induced an increase in the PUFA content of plasma and erythrocyte membranes which was +14.5 and +25.3 %, respectively, at 9 months. This effect was mainly due to the level of DHA and, unexpectedly, to that of AA which continuously increased. This increase in AA was the result of an increased dietary intake (+50 mg/d) and very probably of an increased biosynthesis as demonstrated by the behaviour of di-homo-gamma-linolenic acid. The supplementation resulted in a blood PUFA status comparable with that of young healthy controls. The data are consistent with a strong regulatory action of the dietary treatment on the subjects' lipid metabolism.

In this issue

In this issue

Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid.

Dietary docosahexaenoic acid (DHA), which integrates into tumor cell membranes, has been reported to enhance the efficacy against tumors of cytotoxic drugs that induce reactive oxygen species (ROS). Because ionizing radiation also generate ROS, we initiated a study to determine whether dietary DHA might sensitize mammary tumors to irradiation. Mammary tumors were induced by N-methylnitrosourea (NMU) in Sprague-Dawley rats. The optimal dose of radiation to examine the effect of DHA on tumor response to irradiation was determined to be 18 grays (Gy) using a 4-6 MeV electron beam (according to the depth of the target volume) delivered in a single fraction from a linear accelerator. Two groups of rats were fed a basal diet containing 7% of a mixture of peanut and rapeseed oils enriched with 8% of an oil containing either a low (palm oil) or high (DHASCO oil containing 40% DHA) DHA content. DHA group was equally subdivided into 2 groups without or with addition of vitamin E (100 IU/kg diet). Irradiation was carried out when the first tumor in each rat reached 1.5 cm2 and subsequent change in tumor size was documented over time. DHA level in adipose tissue, taken as a biomarker, was higher in the DHA supplemented group compared to the control group. Vitamin E level in liver, the best storage for this compound, was higher in the vitamin E supplemented DHA group compared to the DHA group. Tumor size decreased by 60% at 12 days after irradiation in the DHA group vs. 31% in the control group (p = 0.03) and 36% in the DHA plus vitamin E group. Therefore, dietary DHA sensitized mammary tumors to radiation. The addition of vitamin E inhibited the beneficial effect of DHA, suggesting that this effect might be mediated by oxidative damage to the peroxidizable lipids.

Long chain polyunsaturate supplementation does not induce excess lipid peroxidation of piglet tissues.

Addition of highly polyunsaturated fatty acids to infant formulas raises the possibility of increased lipid peroxidation. We determined the effects of increasing levels of dietary docosahexaenoic acid (DHA) and arachidonic acid (AA) on lipid peroxidation and peroxidative potential in piglet tissues. Four groups of piglets (n = 6) were bottle-fed a formula containing one of four treatments: no long chain fatty acid (Diet 0) and three different levels of DHA/AA at 1-fold (0.3 %/0.6% FA; Diet 1) 2-fold (0.6 %/1.2% FA; Diet 2) and 5-fold (1.5%/3% FA; Diet 5) concentration used in some human infant formulas, and all with equal amount of vitamin E (5.7 IU/ 100 kcal formula) for four weeks. There were no significant differences between the groups in conjugated diene and glutathione (GSH) levels in the liver, and thiobarbituric acid-reactive substance (TBARS) in plasma. TBARS levels of the erythrocyte membranes increased in a dose-dependent manner when in vitro oxidation was induced with 10 mM hydrogen peroxide (H(2)O(2)) for 30 minutes. The TBARS levels of the liver homogenates of the Diet 5 and Diet 2 groups were significantly different than those of the membranes of the Diet 0 group when the in vitro oxidation was induced with H(2)O(2). The results show that dietary vitamin E effectively prevented lipid peroxidation at the LCP concentrations investigated and suggest that levels presently in infant formulas are sufficient.